Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2015, Article ID 167029, 6 pages
http://dx.doi.org/10.1155/2015/167029
Research Article

Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M. H. Mari Gowda Road, Hombegowda Nagar, Bangalore, Karnataka 560030, India

Received 27 June 2015; Revised 7 October 2015; Accepted 11 October 2015

Academic Editor: Shaji Kumar

Copyright © 2015 Linu A. Jacob et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Cancer Institute, “Surveillance, Epidemiology, and End Results. SEER Cancer Statistics Review 1975–2005,” February 2009, http://seer.cancer.gov/csr/1975_2005/index.html.
  2. G. Juliusson, P. Antunovic, Å. Derolf et al., “Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry,” Blood, vol. 113, no. 18, pp. 4179–4187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F. R. Appelbaum, H. Gundacker, D. R. Head et al., “Age and acute myeloid leukemia,” Blood, vol. 107, no. 9, pp. 3481–3485, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Luger, “Treating the elderly patient with acute myelogenous leukemia,” ASH Education Book, vol. 2010, no. 1, pp. 62–69, 2010. View at Publisher · View at Google Scholar
  5. J. M. Rowe, “Closer to the truth in AML,” Blood, vol. 113, no. 18, pp. 4129–4130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. G. L. Bianchi Scarrà, M. Romani, D. A. Coviello et al., “Terminal erythroid differentiation in the K-562 cell line by 1-beta-D-arabinofuranosylcytosine: accompaniment by c-myc messenger RNA decrease,” Cancer Research, vol. 46, no. 12, pp. 6327–6332, 1986. View at Google Scholar · View at Scopus
  7. G. Juliusson, M. Höglund, K. Karlsson et al., “Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A Randomized Population-Based Phase II Study,” British Journal of Haematology, vol. 123, no. 5, pp. 810–818, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Juliusson, P. Antunovic, Å. Derolf et al., “Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry,” Blood, vol. 113, no. 18, pp. 4179–4187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. K. Al-Ali, N. Jaekel, and D. Niederwieser, “The role of hypomethylating agents in the treatment of elderly patients with AML,” Journal of Geriatric Oncology, vol. 5, no. 1, pp. 89–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Baccarani and S. Tura, “Differentiation of myeloid leukaemic cells: new possibilities for therapy,” British Journal of Haematology, vol. 42, no. 3, pp. 485–487, 1979. View at Publisher · View at Google Scholar · View at Scopus
  11. W. C. Moloney and D. S. Rosenthal, “Treatment of early acute nonlymphoblastic leukemia with low-dose cytosine arabinoside,” in Modern Trends in Human Leukemia Cells IV, R. Neth, R. C. Gallo, T. Graf, K. Mannweiler, and K. Winker, Eds., pp. 59–62, Springer, Berlin, Germany, 1981. View at Google Scholar
  12. M. Housset, M. T. Daniel, and L. Degos, “Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?” British Journal of Haematology, vol. 51, no. 1, pp. 125–129, 1982. View at Publisher · View at Google Scholar · View at Scopus
  13. H. M. Kantarjian, X. G. Thomas, A. Dmoszynska et al., “Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2670–2677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Bashir, S. Geelani, N. Bashir et al., “Role of low dose cytarabine in elderly patients with acute myeloid leukemia: an experience,” South Asian Journal of Cancer, vol. 4, no. 1, pp. 4–6, 2015. View at Publisher · View at Google Scholar
  15. S. Agrawal, W.-K. Hofmann, N. Tidow et al., “The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia,” Blood, vol. 109, no. 9, pp. 3895–3905, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. G. Arnold and S. Ekins, “Time for cooperation in health economics among the modelling community,” PharmacoEconomics, vol. 28, no. 8, pp. 609–613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Weh, R. Zschaber, A. von Paleske, and D. K. Hossfeld, “Treatment of acute myeloid leukemia and myelodysplastic syndrome by low dose cytosine arabinoside,” Haematology and Blood Transfusion, vol. 29, pp. 60–62, 1985. View at Google Scholar · View at Scopus